SCHEMBL22490611

SCHEMBL22490611

Cc1cc(=O)n(C)c2c(O)c(F)ccc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 9/20 0.51
CYP19A1 P11511 9/20 0.51
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.41
KAT2B Q92831 1/20 0.38
HIF1A Q16665 4/20 0.36
BRD9 Q9H8M2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
CASP6 P55212 1/20 0.34
PAX8 Q06710 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30449477 1.00 NQO2 (0.51) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL4328945 0.81 NQO2 (0.51) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL21820274 0.81 NQO2 (0.51) NQO2CYP19A1KDM4EKAT2BBRD9
SCHEMBL21820270 0.75 NQO2 (0.46) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL29712035 0.75 NQO2 (0.46) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL21820236 0.74 NQO2 (0.45) NQO2CYP19A1KDM4EKAT2BBRD9
SCHEMBL12998227 0.74 NQO2 (0.51) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL4330683 0.73 NQO2 (0.45) NQO2CYP19A1KDM4EMAPTKAT2B
SCHEMBL11217793 0.73 MAPT (0.67) NQO2CYP19A1KDM4EMAPTALDH1A1
SCHEMBL30448891 0.73 BRPF1 (0.40) MAPTKAT2BHIF1ABRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111527093-B Antibacterial heterocyclic compounds and synthesis thereof 巴格沃克斯研究有限公司 2023-06-09 CN disclosed
EP-3717490-B1 ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS BUGWORKS RES INC (US) 2023-05-24 EP disclosed
EP-3717490-B1 ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS BUGWORKS RES INC (US) 2023-05-24 EP disclosed
US-11401277-B2 Anti-bacterial heterocyclic compounds and their synthesis Bugworks Research, Inc. (US) 2022-08-02 US disclosed
US-20210070772-A1 ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS Bugworks Research, Inc. 2021-03-11 US disclosed
EP-3717490-A1 ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS Bugworks Research, Inc. (US) 2020-10-07 EP disclosed
CN-111527093-A Antibacterial heterocyclic compounds and synthesis thereof 巴格沃克斯研究有限公司 2020-08-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070772-A1 ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS HLA-B, BAX, REN NQO2 1426/4885CYP19A1 1627/4885KDM4E 4263/4885
US-11401277-B2 Anti-bacterial heterocyclic compounds and their synthesis HLA-B, BAX, REN NQO2 1426/4885CYP19A1 1627/4885KDM4E 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.